Aliskiren(CAS No.173334-58-2) is an orally active renin inhibitor. It blocks angiotensin original cleavage to angiotensin I, which is the first step in blocking the renin - angiotensin system and it is also the step of speed - limite .

Compared with placebo, three doses of Aliskiren significantly reduced sitting DBP and SBP (P <.001). Antihypertensive effect of Aliskren 150 mg approaches to the effect of Irbesartan 150 mg (the average sitting position reduce DBP 9.5 + 8.0 and 9.0 + 7.9 mmHg lower SBP; respectively 10.8 + -- -- 12.4 and 12.5 + 14.2 mmHg); the average sitting position DBP of Aliskiren 300 mg and 600 mg is significantly greater than that of irbesartan 150mg (P <.05). Safety and tolerability of Aliskren and Irebesartan are similar to placebo.

Usually, the recommended starting dose for treating high blood pressure is 150 mg once daily. Your healthcare provider may increase your Tekturna dosage to 300 mg once daily if necessary.